临床试验/NCT01890993

NCT01890993已完成不适用

Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

Novo Nordisk A/S0 个研究点目标入组 952 人开始时间: 2013年8月最近更新: 2015年5月21日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: Novo Nordisk A/S
入组人数: 952
主要终点: Change in HbA1c (glycosylated haemoglobin)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

This study is conducted in Europe. The aim of this study is to demonstrate the clinical effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in routine primary care in Europe.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Retrospective

入排标准

性别: All
接受健康志愿者: 否

入选标准

•Patients treated with liraglutide or DPP-4 inhibitors, according to license in respective participating country with data available for 12 (+/- 2) months

排除标准

•Patients treated with liraglutide or DPP-4 inhibitors, outside of license in respective participating country

研究组 & 干预措施

Liraglutide

干预措施: liraglutide (Drug)

DPP-4

干预措施: liraglutide (Drug)

结局指标

主要结局

Change in HbA1c (glycosylated haemoglobin)

时间窗: Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)

次要结局

Change in body weight(Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2))
Change in systolic blood pressure(Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2))

研究者

发起方

Novo Nordisk A/S

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

不适用

Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2

NCT00704223Novo Nordisk A/S619

已完成

3 期

Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 YearsFoetal Growth ProblemSmall for Gestational Age

NCT00184691Novo Nordisk A/S78

已完成

4 期

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADsDiabetesDiabetes Mellitus, Type 2

NCT00537277Novo Nordisk A/S161

已完成

不适用

Efficacy and Safety of Levemir® Used as Basal InsulinDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes

NCT01548248Novo Nordisk A/S631

已完成

不适用

A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in SwedenDiabetesDiabetes Mellitus, Type 2

NCT02077946Novo Nordisk A/S1,059